Story thread · 2 reports / 2 sources
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
endpts.com · 4h · first report
Cue Biopharma said Sunday its chronic hives candidate cleared a mid-stage trial, marking its first clinical data since its strategic pivot from cancer into immunology. In a Phase 2 China study in chronic spontaneous urticaria ...
The coverage
- Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
finance.yahoo.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.